ReviewAntibody therapeutics2026

Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy.

Cunnan Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.